Evidence map›Paper›PMID 39293979›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Pembrolizumab-associated Neuronopathy with Improved Lower Limb Somatosensory Evoked Potential After Intravenous Methylprednisolone Treatment.

Keisuke Tachiyama, Hiroyuki Naito, Masahiro Nakamori, Shiro Aoki, Hirofumi Maruyama

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keisuke TachiyamaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan.
Hiroyuki NaitoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan.
Masahiro NakamoriDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan.
Shiro AokiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan.
Hirofumi MaruyamaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cases of neuronopathy associated with immune checkpoint inhibitors (ICIs) have rarely been reported. We herein report a case of ICI-associated neuronopathy. A 54-year-old man underwent chemotherapy for right maxillary sinus cancer. Two months after pembrolizumab treatment, diarrhea, worsening of abnormal sensations, and severe ataxia of the lower limbs were observed. Somatosensory evoked potentials (SEPs) with tibial nerve stimulation showed disappearance of the N21 waveform. A colonic biopsy suggested ICI-associated colitis. Based on these findings, the patient was diagnosed with ICI-associated neuronopathy. Clinical symptoms and SEP findings improved markedly after two courses of intravenous methylprednisolone.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalEvoked Potentials, SomatosensoryImmune Checkpoint InhibitorsMethylprednisoloneAdministration, IntravenousHumansLower ExtremityMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsMethylprednisolonepembrolizumabimmune checkpoint inhibitorimmune-related adverse eventsinterleukin-6neuronopathypembrolizumabsomatosensory evoked potentials

Identifiers

PMID39293979
PMCPMC12120217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.